Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Basmisanil?

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

UCB departs industry trade group BIO, following Pfizer’s exit late last year

Brussels-based biopharma company UCB confirmed Thursday that it decided not to renew its membership in the industry group BIO in 2024, the second high-profile exit

January 5, 2024

Trump surrogates hint at how he could reshape U.S. health care policy

WASHINGTON — Seven months before the presidential election, Donald Trump’s health care priorities remain fuzzy at best. But one thing is certain: A second Trump

April 23, 2024

CMN-005 by CoImmune for Mantle Cell Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Mantle Cell Lymphoma.

September 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.